Day: January 5, 2026

Lassila & Tikanoja PlcStock exchange release5 January 2026 at 5.50 PM EET Lassila & Tikanoja Plc – Managers’ Transactions Lassila & Tikanoja Plc has received the following notification under Article 19 of the Market Abuse Regulation, which concerns shares in Lassila & Tikanoja Plc received by a manager or their closely associated person as demerger consideration in the partial demerger of Luotea Plc. ____________________________________________ Person subject to the notification requirementName: Tuija KalpalaPosition: Member of the Board/Deputy memberIssuer: Lassila & Tikanoja OyjLEI: 636700EBB0SA4501AT18Notification type: INITIAL NOTIFICATIONReference number: 137391/4/4 ____________________________________________ Transaction date: 2025-12-31Outside a trading venueInstrument type: SHAREISIN: FI4000592472Nature...

Lassila & Tikanoja PlcStock exchange release5 January 2026 at 5.25 PM EET Lassila & Tikanoja Plc’s ten largest shareholders Trading in the new Lassila & Tikanoja Plc’s (“Lassila & Tikanoja”) shares commenced on the official list of Nasdaq Helsinki Ltd on 2 January 2026, following the completion of the partial demerger of Lassila & Tikanoja plc (currently Luotea Plc) on 31 December 2025, under the share trading code “LASTIK” and ISIN code FI4000592472. The following table sets forth the ten largest shareholders of Lassila & Tikanoja registered in the shareholder register maintained by Euroclear Finland Oy as at 2 January 2026. The percentages are rounded.Shareholder Shares and Votes %     Evald ja Hilda Nissi Foundation 3,496,487 9.15Protector Forsikring ASA1) 2,014,377 5.27Nordea Nordic Small...

LOS ANGELES, Jan. 05, 2026 (GLOBE NEWSWIRE) — Limitless X Holdings Inc. (OTCQX: LIMX), a diversified global consumer products, wellness, entertainment, and lifestyle company founded by entrepreneur Jas Mathur, today announced that its Board of Directors has appointed Daniel Sanders as President, effective immediately. Mr. Sanders brings over 20 years of senior executive experience across consumer nutraceuticals, wellness, product development, large-scale GMP manufacturing, and national retail distribution. Throughout his career, he has been part of executive and operational teams responsible for developing, manufacturing, and scaling products distributed through major U.S. retailers, including Walmart, Sam’s Club, Whole Foods, Target, Kroger, Sprouts, GNC, and Costco, as well as private-label manufacturing for the Whole Foods 365...

New AHV85003/AHV85043 chipset joins the flagship AHV85311 integrated solution with industry’s first complete family of noise-eliminating, self-powered SiC gate driversAHV85003/AHV85043AHV85003/AHV85043MANCHESTER, N.H., Jan. 05, 2026 (GLOBE NEWSWIRE) — Allegro MicroSystems, Inc. (“Allegro”) (Nasdaq: ALGM), a global leader in power and sensing solutions for motion control and energy-efficient systems, today announced the strategic expansion of its Power-Thru™ isolated gate driver portfolio with the launch of the AHV85003/AHV85043 chipset. Joining the flagship AHV85311 integrated solution, this expanded family creates a complete ecosystem for high-voltage silicon carbide (SiC) designs in AI data centers, electric vehicles (EVs), and clean energy systems. The solution simplifies the design challenge in power conversion...

CHARLOTTE, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) — SPX Technologies, Inc. (NYSE: SPXC) (“SPX” or the “Company”) is pleased to announce the appointment of Daniel Whitman as its new Vice President, General Counsel & Secretary, effective January 5, 2026. An accomplished and strategic leader, Mr. Whitman brings a unique perspective to this role. He joins SPX following a 20-year career at Parker Hannifin, including the last 14 years as Vice President, Law, Deputy General Counsel and Assistant Secretary, serving as the legal team’s principal deputy with responsibility for all commercial and operational support activities. “The addition of Daniel to the SPX Technologies team strengthens our organization in a number of meaningful ways,” said SPX Technologies President and CEO Gene Lowe. “His extensive legal and executive leadership...

DELAWARE, Ohio, Jan. 05, 2026 (GLOBE NEWSWIRE) — In a release issued under the same headline on Monday, January 5th by Greif, Inc. (NYSE: GEF, GEF.B), please note that the dates of reporting the first quarter financial results and the conference call should be Tuesday, January 27 and Wednesday, January 28 respectively. The corrected release follows: Greif, Inc. (NYSE: GEF, GEF.B), a global leader in industrial packaging products and services, announced today it will report the company’s 2026 first quarter financial results after the market closes on Tuesday, January 27, 2026. A conference call will be held on Wednesday, January 28, 2026, at 8:30 a.m. ET to discuss the quarter results. Greif will provide conference call slides in combination with the earnings press release. The conference call will include management’s prepared...

-Coherus Oncology formally introduces non-proprietary name: tagmokitug- -Publication shows picomolar affinity for CCR8 with no off-target binding and proof-of- mechanism in preclinical and clinical studies- -Data show CCR8 target is present with high prevalence and density in many solid tumors- REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) — Coherus Oncology, Inc. (NASDAQ: CHRS) today announced the publication of preclinical and clinical biomarker research in Molecular Cancer Therapeutics describing the high selectivity, picomolar binding affinity and significant effector mediated killing of CCR8+ cells of its investigational anti-CCR8 monoclonal antibody. The findings show that the antibody, now named tagmokitug, demonstrated no off-target binding, and selectively eliminates CCR8+ T regulatory cells and not other T cells,...

CHICAGO, Jan. 05, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories, has entered into a manufacturing and supply agreement to undertake the full end-to-end production of the pharmaceutical product PathMuscle for Libytec Pharmaceutical S.A., the product’s exclusive distributor in Greece. Under the terms of the agreement, Cosmos Health will be responsible for the complete manufacturing of the finished pharmaceutical product, including formulation, production, quality control, and product release, in accordance with applicable regulatory requirements. PathMuscle is an advanced generic pharmaceutical product formulated as a fixed-dose combination of...